Franklin Resources Inc. acquired a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 821,233 shares of the company's stock, valued at approximately $5,675,000. Franklin Resources Inc. owned approximately 0.22% of GoodRx as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of GDRX. nVerses Capital LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at about $33,000. Plato Investment Management Ltd purchased a new position in GoodRx during the second quarter valued at approximately $43,000. EP Wealth Advisors LLC bought a new position in GoodRx in the third quarter worth approximately $73,000. Dark Forest Capital Management LP purchased a new stake in GoodRx during the second quarter worth $86,000. Finally, Sanctuary Advisors LLC bought a new stake in GoodRx during the 3rd quarter valued at $85,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.
Shares of GDRX stock opened at $4.52 on Tuesday. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The stock has a market cap of $1.72 billion, a P/E ratio of -150.67, a P/E/G ratio of 3.54 and a beta of 1.29. The stock has a 50 day moving average of $5.33 and a 200 day moving average of $6.96. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.
Several research analysts have recently commented on GDRX shares. Mizuho assumed coverage on GoodRx in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price target for the company. Citigroup decreased their price target on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Morgan Stanley lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Finally, Barclays reduced their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and a consensus target price of $8.37.
Get Our Latest Stock Report on GoodRx
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.